In this issue

Issue 111 • October 2021

Biologics have revolutionised drug development across medical sectors, being used to treat a wide array of diseases and conditions. But, with each new advancement in the sector comes a new challenge for the packaging solution used to ensure the safety and stability of these complex drugs throughout their designated shelf life.

To find out more, we unpack key developments in biologics packaging that are helping practitioners and patients to store and administer treatments.

Keeping with the topic of living medicines, scientists have reportedly identified the role bacteria can play in cancer growth and resistance to chemotherapy drugs – but these tiny microbes could prove useful in treating the disease, too. To learn more, we examine the promises and limitations of therapeutic bacteria as an approach to treating cancer. 

Elsewhere in this issue, we take a look at the marred history of HIV vaccine trials, ask if Covid-19 has exposed serious weaknesses in the US pharma supply chain, and find out why innovation in pharmacovigilance is necessary in a post-pandemic world.

All this, plus the latest insight and analysis from GlobalData.

Eloise Mclennan, editor

Go to article: Home | Unpacking innovation in biologics Go to article: In this issueGo to article: ContentsGo to article: MyonexGo to article: Controlant Company InsightGo to article: ControlantGo to article: SHL MedicalGo to article: LabcorpGo to article: ReutersGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: TQS Integration Company InsightGo to article: TQS IntergrationGo to article: Biesterfeld Go to article: CommentGo to article: Biotech and China: a global opportunityGo to article: Intranasal ketamine could effectively treat phantom painGo to article: EU biosimilar wave slows as biosimilar approvals decrease in the EUGo to article: Biosynth Carbosynth Company InsightGo to article: Biosynth CarbosynthGo to article:  Molnár-Institute Company Insight Go to article: Molnar-InstituteGo to article: SkyepharmaGo to article: In DepthGo to article: Unpacking the complex challenge of biologicsGo to article: Living medicines: using bacteria to fight cancerGo to article: The marred history of HIV vaccine trialsGo to article: Has Covid-19 exposed the weakness of the US pharma supply chain?Go to article: How the pandemic pushed pharmacovigilance to innovateGo to article: ExeVir: the llama-derived antibody that could fight Covid-19Go to article: BEA TechnologiesGo to article: WatlowGo to article: DuojectGo to article: ButterworthGo to article: In DataGo to article: Data: Big Data hiring efforts in pharmaGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article: Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue